Wednesday, July 8, 2026

biotech · Acute Myeloid Leukemia (AML) · Ovarian Cancer · STRO

SUTRO BIOPHARMA

SUTRO BIOPHARMA is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker STRO. Primary therapeutic focus areas include Acute Myeloid Leukemia (AML), Ovarian Cancer, Lung Cancer,

South San Francisco, USA HQ
2003 Founded
212 Employees
Public company Type
STRO · NYSE Ticker
Company details
Status
Public
HQ
South San Francisco, USA
Founded
2003
Employees
212
Programs
10
Drugs
21
Patents
34
Clinical program

STRO-002

Phase 2 · mab · Neoplasm Malignant

STRO-002 for Neoplasm Malignant is a Phase 2 program (mab) at SUTRO BIOPHARMA, INC. with 1 ClinicalTrials.gov record(s).

Internal code TSL-B2276-1-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
SUTRO BIOPHARMA, INC.
Phase
Phase 2
Modality
mab
Indication
Neoplasm Malignant
Status
completed
Trials
1